Do Not Do Recommendation

 

Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol/mol [1.0%] in HbA1c and a weight loss of at least 3% of initial body weight in 6 months). [2015]

Do Not Do Recommendation Details

Recommendation:

Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol/mol [1.0%] in HbA1c and a weight loss of at least 3% of initial body weight in 6 months). [2015]

Interventions:
GLP-1 mimetic therapy

Source guidance details

Guidance:
Type 2 diabetes in adults: management (NG28)
Published date:
December 2016
Paragraph number:
1.6.29
Page number:
23

View all NICE do not do from this Guidance